Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

My Career in Geriatric Oncology.

JCO oncology practice·2025
Same author

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Missed Opportunities in Geriatric Oncology Research.

The oncologist·2023
Same author

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.

JNCI cancer spectrum·2022
Same author

Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers.

The oncologist·2022
Same author

From Assessment to Implementation and Beyond in Cancer and Aging Research.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2021
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Videos

Beyond Performance Status: Optimize Cancer Care in Older Adults.

Stuart M Lichtman1,2

  • 1Geriatric Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 13, 2026
PubMed
Summary
This summary is machine-generated.

Geriatric assessment (GA) identifies vulnerabilities in older cancer patients missed by performance status (PS) tools. GA-guided interventions reduce treatment toxicity by 10-20% without impacting survival, improving care for this population.

Related Experiment Videos

Area of Science:

  • Geriatric oncology
  • Clinical trial methodology
  • Evidence-based medicine

Background:

  • Older adults represent a significant majority of cancer diagnoses and deaths.
  • Current performance status (PS) tools are outdated and fail to capture geriatric complexities.
  • Geriatric assessment (GA) identifies significant deficits in patients with seemingly good PS.

Purpose of the Study:

  • To highlight the limitations of traditional PS tools in older cancer patients.
  • To present evidence supporting the integration of comprehensive GA into cancer care.
  • To advocate for a shift from chronologic age to functional reserve assessment.

Main Methods:

  • Review of landmark randomized controlled trials (e.g., GAP70+, GAIN, INTEGERATE, COACH, PERI-OP).
  • Analysis of evidence for GA in specific cancer types and hematologic malignancies.
  • Evaluation of practical screening tools (CARG, CRASH, Geriatric 8, VES-13) for feasibility.

Main Results:

  • Comprehensive GA evaluates functional status, cognition, nutrition, comorbidities, polypharmacy, and social support.
  • GA-guided interventions reduced severe treatment toxicities (grade 3-5) by 10%-20% in trials.
  • Benefits are achieved through treatment modification and enhanced supportive care.

Conclusions:

  • GA provides crucial insights beyond PS, identifying vulnerabilities in older adults.
  • Integrating GA into treatment decisions is evidence-based and ethically imperative.
  • A proposed algorithm facilitates GA integration with existing cancer guidelines.